SCHEMBL20239154

SCHEMBL20239154

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)cc(NCc3ccc(OC)cc3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.46
VNN1 O95497 7/20 0.44
KDM4E B2RXH2 1/20 0.42
CLK4 Q9HAZ1 3/20 0.40
CLK1 P49759 2/20 0.40
CLK2 P49760 2/20 0.40
DYRK1A Q13627 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
MAP2K7 O14733 1/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
PTGS2 P35354 1/20 0.38
HTT P42858 1/20 0.38
HIF1A Q16665 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
TP53 P04637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239250 0.90 DGAT2 (0.57) DGAT2VNN1KDM4ECLK4CLK1
SCHEMBL18249759 0.90 DGAT2 (0.49) DGAT2VNN1KDM4ECLK4CLK1
SCHEMBL20239153 0.85 DGAT2 (0.43) DGAT2VNN1KDM4ECLK4CLK1
SCHEMBL20239261 0.85 DGAT2 (0.51) DGAT2VNN1KDM4ECLK4CLK1
SCHEMBL20239159 0.85 LOXL2 (0.45) CLK4DYRK1ANPC1RAB9AKMT2A
SCHEMBL20472861 0.84 VNN1 (0.45) DGAT2VNN1CLK4CLK1CLK2
SCHEMBL20239143 0.83 VNN1 (0.44) DGAT2VNN1CLK4CLK1CLK2
SCHEMBL20239227 0.81 DGAT2 (0.56) DGAT2VNN1KDM4ECLK4CLK1
SCHEMBL20239323 0.81 SLC6A4 (0.43) DGAT2VNN1CLK4CLK1CLK2
SCHEMBL20239145 0.81 DYRK1A (0.46) VNN1KDM4ECLK4DYRK1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3148/4885KDM4E 4070/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3615/4885KDM4E 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.